MYMETICS CORPORATION | 0,008 Euro | 0,00 0 % | |
| WKN: 918588 ISIN: US62856A1025 Ticker-Symbol: NKQ | Berlin | 19.06.13 | 08:39 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 15.04. | MYMETICS CORP - 8-K, Entry into a Material Definitive Agreement Financial Statements and Exhibits | - | SEC Filings | |
| 21.02. | Data Published in PLOS ONE Show Mymetics' HIV-1 Innovative Vaccine is Safe and Elicits Strong Immunogenicity / - Vaccine-induced mucosal antibodies may contribute to reduce sexually transmitted HIV-1 - Immunogenicity of the HIV-1 vaccine confirmed both | 83 | Marketwired | |
| EPALINGES, SWITZERLAND -- (Marketwire) -- 02/21/13 -- Results from a randomized study published in PLOS ONE(1) today demonstrate that Mymetic' innovative HIV-1 (Human Immunodeficiency Virus type 1)... Mehr lesen zu: Data Published in PLOS ONE Show Mymetics' HIV-1 Innovative Vaccine is Safe and Elicits Strong Immunogenicity / - Vaccine-induced mucosal antibodies may contribute to reduce sexually transmitted HIV-1 - Immunogenicity of the HIV-1 vaccine confirmed both | ||||
| 27.11. | Mymetics Announces Change of Directors and Management / - Ronald Kempers appointed President and CEO - Departure of Dr. Christopher S. Henney and Grant Pickering | 46 | Marketwired | |
| EPALINGES, SWITZERLAND -- (Marketwire) -- 11/27/12 -- Mymetics Corporation (OTCBB: MYMX), a pioneer in the development of vaccines that use the human mucosal system, the body's first line of defense... Mehr lesen zu: Mymetics Announces Change of Directors and Management / - Ronald Kempers appointed President and CEO - Departure of Dr. Christopher S. Henney and Grant Pickering | ||||
| 21.08. | Mymetics Selects RSV Program as Lead Development Program from Its Second Generation Virosome Platform / Announces Strategic Appointments Including George Kemble to SAB | 55 | Marketwired | |
| EPALINGES, SWITZERLAND -- (Marketwire) -- 08/21/12 -- Mymetics Corporation (OTCQB: MYMX), a leader in the development of mucosal and virosomal-based vaccines for infectious diseases, announced today... Mehr lesen zu: Mymetics Selects RSV Program as Lead Development Program from Its Second Generation Virosome Platform / Announces Strategic Appointments Including George Kemble to SAB | ||||
4 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| MEDIGENE | 0,975 | +0,31 % | Medigene: Kursziel steigt vor Zusammenlegung |
| MORPHOSYS | 38,435 | -0,17 % | MorphoSys AG: Veröffentlichung gem. § 26 Abs.1 WpHG mit dem Ziel der europaweiten Verbreitung |
| EVOTEC | 2,774 | +0,14 % | Termine 12.6., u.a. Conergy, Evotec, Fraport, Intershop |
| QIAGEN | 14,775 | +0,51 % | QIAGEN-Aktie kommt wieder auf die Beine! |
| BB BIOTECH | 91,38 | +0,13 % | BB Biotech AG: Veröffentlichung gem. § 26 Abs.1 WpHG mit dem Ziel der europaweiten Verbreitung |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von